2020. Durability of Response in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol over 216 Weeks: Post-Hoc Analyses from the RAPID-PsA Study. SKIN The Journal of Cutaneous Medicine. 4, 1 (Jan. 2020), S2.